Your browser doesn't support javascript.
loading
Process mapping strategies to prevent subcutaneous implantable cardioverter-defibrillator infections.
Weiss, Raul; Mark, George E; El-Chami, Mikhael F; Biffi, Mauro; Probst, Vincent; Lambiase, Pier D; Miller, Marc A; McClernon, Timothy; Hansen, Linda K; Knight, Bradley P; Baddour, Larry M.
Affiliation
  • Weiss R; Department of Internal Medicine, Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Mark GE; Department of Cardiology, Cooper University Hospital, Camden, New Jersey, USA.
  • El-Chami MF; Division of Cardiology, Section of Electrophysiology, Emory University Hospital, Atlanta, Georgia, USA.
  • Biffi M; University of Bologna, and Azienda Ospedaliera di Bologna, Bologna, Italy.
  • Probst V; L'Institut du Thorax, Cardiologic Department and Reference Center for Hereditary Arrhythmic Diseases, Nantes, France.
  • Lambiase PD; UCL Institute of Cardiovascular Science, and Barts Heart Center, London, UK.
  • Miller MA; Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, New York, New York, USA.
  • McClernon T; People Architects Inc., Minneapolis, Minnesota, USA.
  • Hansen LK; Boston Scientific, St. Paul, Minnesota, USA.
  • Knight BP; Medical Director of Cardiac Electrophysiology, Center for Heart Rhythm Disorders Bluhm Cardiovascular Institute, Northwestern Memorial Hospital, Chicago, Illinois, USA.
  • Baddour LM; Department of Medicine, Division of Infectious Diseases, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
J Cardiovasc Electrophysiol ; 33(7): 1628-1635, 2022 07.
Article in En | MEDLINE | ID: mdl-35662315
ABSTRACT

BACKGROUND:

Infection remains a major complication of cardiac implantable electronic devices and can lead to significant morbidity and mortality. Implantable devices that avoid transvenous leads, such as the subcutaneous implantable cardioverter-defibrillator (S-ICD), can reduce the risk of serious infection-related complications, such as bloodstream infection and infective endocarditis. While the 2017 AHA/ACC/HRS guidelines include recommendations for S-ICD use for patients at high risk of infection, currently, there are no clinical trial data that address best practices for the prevention of S-ICD infections. Therefore, an expert panel was convened to develop a consensus on these topics.

METHODS:

An expert process mapping methodology was used to achieve consensus on the appropriate steps to minimize or prevent S-ICD infections. Two face-to-face meetings of high-volume S-ICD implanters and an infectious diseases specialist, with expertise in cardiovascular implantable electronic device infections, were conducted to develop consensus on useful strategies pre-, peri-, and postimplant to reduce S-ICD infection risk.

RESULTS:

Expert panel consensus on recommended steps for patient preparation, S-ICD implantation, and postoperative management was developed to provide guidance in individual patient management.

CONCLUSION:

Achieving expert panel consensus by process mapping methodology for S-ICD infection prevention was attainable, and the results should be helpful to clinicians in adopting interventions to minimize risks of S-ICD infection.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Defibrillators, Implantable Type of study: Clinical_trials / Etiology_studies / Guideline Limits: Humans Language: En Journal: J Cardiovasc Electrophysiol Journal subject: ANGIOLOGIA / CARDIOLOGIA / FISIOLOGIA Year: 2022 Type: Article Affiliation country: United States

Full text: 1 Database: MEDLINE Main subject: Defibrillators, Implantable Type of study: Clinical_trials / Etiology_studies / Guideline Limits: Humans Language: En Journal: J Cardiovasc Electrophysiol Journal subject: ANGIOLOGIA / CARDIOLOGIA / FISIOLOGIA Year: 2022 Type: Article Affiliation country: United States